Argenica Therapeutics Ltd ( (AU:AGN) ) has provided an announcement.
Argenica Therapeutics announced significant preclinical study results demonstrating that their therapeutic candidate, ARG-007, effectively reduces axonal injury and neuroinflammation in cases of moderate traumatic brain injury (TBI). The treatment showed promising outcomes by restoring biomarker levels to those of non-injured animals, suggesting its potential to mitigate both acute and chronic effects of TBI, potentially reshaping therapeutic approaches in the industry.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following brain injury.
YTD Price Performance: 11.11%
Average Trading Volume: 113,059
Technical Sentiment Consensus Rating: Sell
See more insights into AGN stock on TipRanks’ Stock Analysis page.